Watchlist Price Alert

Co-Diagnostics Inc. (CODX)

NASDAQ: CODX · Real-Time Price · USD

0.31

-0.03 (-10.01%)

At close: May 15, 2025, 3:59 PM

0.32

3.21%

After-hours: May 15, 2025, 07:57 PM EDT

-10.01% (1D)

Bid	0.26
Market Cap	10.29M
Revenue (ttm)	1M
Net Income (ttm)	-35.86M
EPS (ttm)	-1.24
PE Ratio (ttm)	-0.25
Forward PE	3.81
Analyst	Hold

Ask	0.35
Volume	1,261,812
Avg. Volume (20D)	250,226
Open	0.35
Previous Close	0.34
Day's Range	0.27 - 0.38
52-Week Range	0.27 - 2.23
Beta	0.84

About CODX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CODX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CODX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Co-Diagnostics has released their quartely earnings on May 8, 2025:

Revenue of $50.28K misses estimates by $324.72K, with -89.25% YoY decline.

EPS of -0.24 exceeds estimates by 0.09, with 22.58% YoY growth.

Why Price Moved

8 months ago

+7.2%

Co-Diagnostics shares are trading higher after the... Unlock content with Pro Subscription

8 months ago

+12.9%

Co-Diagnostics shares are trading higher after the CDC announced free at home Covid 19 test delivery programs will reopen in late September.

News

1 week ago · seekingalpha.com

Co-Diagnostics, Inc. (CODX) Q1 2025 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Br...

1 week ago · zacks.com

Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.31 per share a year ago.

1 month ago · zacks.com

All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy

CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · zacks.com

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.

1 month ago · seekingalpha.com

Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants ...

2 months ago · benzinga.com

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

On Friday, Co-Diagnostics, Inc. CODX withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test for 510(k) clearance.